Category Archives: Clinical Cardiology

A single educational mailing to patients with A-fib and their doctors is not enough to increase uptake of oral anticoagulation for stroke prevention, results of the IMPACT-AFib trial show. Continue reading →

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) supported new data, presented at ESC Congress 2020, the annual meeting of the European Society of Cardiology (ESC), held from August 29 - September 1, 2020, adding to the growing body of knowledge on VASCEPA (icosapent ethyl) in patients at risk for major adverse cardiovascular events. Continue reading →

Physical activity not only is safe, but necessary for people with heart conditions, according to the authors of new exercise guidelines released this week by the European Society of Cardiology. Continue reading →

Launched in 2019, the VersaCross solution is the world's first all-in-one solution for left-heart access-to-delivery. Continue reading →

Evolocumab treatment in addition to statin therapy was found to lower cardiovascular risk in patients with metabolic syndrome (MetS) and stable atherosclerotic cardiovascular (CV) disease, according to the results of a randomized clinical trial published in JAMA Cardiology. Patients (n=27,342) with stable atherosclerotic CV disease and on a statin regimen from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk trial (FOURIER; ClinicalTrials.gov Identifier: NCT01764633), which was conducted between 2013 and 2016, were stratified according to the National Cholesterol Education Program Adult Treatment Panel III MetS criteria. Patients were randomly assigned to receive the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab (subcutaneous injection of 140 mg every 2 weeks or 420 mg per month) or placebo. Continue reading →

A Latest Business Intelligence report released by Market Intellica (MI) with the title Nanomedicine Market Research: Global Status & Forecast by Geography, Type & Application (2016-2026) has abilities to raise as the most important market globally as it has remained to play an amazing role in creating progressive impacts on the entire economy. The World Nanomedicine market report offers energetic visions to conclude and study the market size, market hopes, and competitive backgrounds Continue reading →

August 31, 2020 08:00 ET | Source: Kiniksa Pharmaceuticals, Ltd. HAMILTON, Bermuda, Aug Continue reading →

NEW YORK, Sept. Continue reading →

Sophia Antipolis, France August 31, 2020:Dramatic reductions in the risk of heart attacks in patients with diabetes coincides with major increases in the use of preventive medications. Thats the finding of late breaking research presented today at ESC Congress 2020.1 Our results suggest that when patients are diagnosed with type 2 diabetes, starting medications to prevent cardiovascular disease has a substantial impact on the risk of heart attacks and premature death, said principal investigator Dr. Continue reading →

Sophia Antipolis, France September 1, 2020:Fainting affects one in two people during their lifetime. Those with recurrent episodes are often afraid to socialise or go to work. Today researchers report the first effective therapy. Continue reading →